Research / AVGO / Fundamental state Inspectable configuration
State dimensions Filing 0001730168-20-000045 General Corporate
Debt relative to revenue RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.debt_to_revenue
762.43% · OPTIONAL · NOT_ENOUGH_HISTORY
Capex intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.capex_revenue_ratio
1.84% · OPTIONAL · NOT_ENOUGH_HISTORY
Operating cash generation RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
39.64% · OPTIONAL · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
1.19% · CORE · NOT_ENOUGH_HISTORY
Inventory pressure RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
16.11% · OPTIONAL · NOT_ENOUGH_HISTORY
Gross margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.gross_margin
55.72% · CORE · NOT_ENOUGH_HISTORY
Operating margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.operating_margin
12.19% · CORE · NOT_ENOUGH_HISTORY
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
22.00% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
9.30% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 23 states Self-history eligible
Feb 3, 2019 0/8 normalized Level 3 May 5, 2019 0/9 normalized Level 3 Aug 4, 2019 0/9 normalized Level 3 Nov 3, 2019 0/9 normalized Level 3 Feb 2, 2020 0/9 normalized Level 3 May 3, 2020 6/9 normalized Level 3 Aug 2, 2020 8/9 normalized Level 3 Nov 1, 2020 8/9 normalized Level 3 Jan 31, 2021 8/9 normalized Level 3 May 2, 2021 9/9 normalized Level 3 Aug 1, 2021 9/9 normalized Level 3 Oct 31, 2021 9/9 normalized Level 3 Jan 30, 2022 9/9 normalized Level 3 May 1, 2022 9/9 normalized Level 3 Jul 31, 2022 9/9 normalized Level 3 Oct 30, 2022 8/8 normalized Level 3 Jan 29, 2023 8/8 normalized Level 3 Apr 30, 2023 8/8 normalized Level 3 Jul 30, 2023 8/8 normalized Level 3 Aug 2, 2026 9/9 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Increased
Previous 145.14%
Current 762.43%
Delta 617.28% Capex Intensity Decreased
Previous 1.91%
Current 1.84%
Delta -0.07% Cash Generation Decreased
Previous 42.91%
Current 39.64%
Delta -3.27% Growth Decreased
Previous 8.39%
Current 1.19%
Delta -7.20% Inventory Pressure Increased
Previous 3.87%
Current 16.11%
Delta 12.25% Margin Increased
Previous 55.24%
Current 55.72%
Delta 0.48% Profitability Decreased
Previous 15.24%
Current 12.19%
Delta -3.05% R And D Intensity Increased
Previous 20.78%
Current 22.00%
Delta 1.22% Sbc Intensity Decreased
Previous 9.67%
Current 9.30%
Delta -0.37% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.